Obicetrapib and SGLT2 Inhibitor Fixed-Dose Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes often require progression to insulin-dependence due to inadequate glycemic control, and are associated with side effects such as weight gain.
Innovation Solution
A pharmaceutical composition comprising obicetrapib, a CETP inhibitor, and an SGLT2 inhibitor, administered in a fixed dose formulation to treat metabolic disorders like type 2 diabetes, delaying progression to insulin-dependence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapy is used to treat type 2 diabetes, then treatment simplicity is maintained, but glycemic control becomes inadequate leading to progression to insulin-dependence
Solution Approach 1:
The patent combines obicetrapib (a CETP inhibitor) and an SGLT2 inhibitor into a single fixed-dose combination pharmaceutical composition. This merging of two different mechanisms of action into one treatment regimen improves glycemic control reliability while maintaining treatment simplicity through single-administration convenience.
2Reliability
If sulfonylurea and thiazolidinedione therapies are used to improve glycemic control, then blood glucose levels are reduced, but weight gain occurs as a side effect
Solution Approach 1:
The patent employs a different mechanism of action (CETP inhibition combined with SGLT2 inhibition) that achieves glycemic control through alternative physiological pathways. This parameter change in therapeutic approach allows effective glucose control without the weight gain side effect associated with traditional sulfonylurea and thiazolidinedione therapies.
3Reliability
If combination therapy is used to improve glycemic control, then treatment efficacy increases, but side effects and treatment complexity increase
Solution Approach 1:
The patent merges obicetrapib and SGLT2 inhibitor into a single fixed-dose combination product that is administered once daily. This approach maintains the improved glycemic control efficacy of combination therapy while simplifying treatment ease by eliminating the need for multiple separate administrations and reducing pill burden.
Data Source
AI summary
Provided herein is a pharmaceutical composition comprising obicetrapib, or a pharmaceutically acceptable salt thereof, and an SGTL2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are dosage forms including the same. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided are processes for the preparation of fixed dose formulations of obicetrapib and an SGTL2 inhibitor, and methods for using the same in the treatment of a metabolic disorder (e.g., type 2 diabetes). Also provided are methods of treating or preventing a metabolic disorder in a subject who has or is at risk of developing a metabolic disorder, comprising: administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.